Charles River Laboratories Intl. Inc vs Kingsoft Cloud Holdings Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $303.14 (market cap $14.23B), while Kingsoft Cloud Holdings Limited trades at $9.25 (market cap $2.71B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.3× Kingsoft Cloud Holdings Limited's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Kingsoft Cloud Holdings Limited for 12 Days on average.
| CRL | KC | |
|---|---|---|
Market Cap | $14.23B | $2.71B |
Volume | 1,176,885 | 1,993,765 |
Sector | Health | Technology |
52-Week High | $310.77 | $18.21 |
52-Week Low | $149.93 | $8.58 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $17.06B | $3.03B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Kingsoft Cloud (KC) trades at $9.23 with no recent price movement. The stock shows bearish technical signals with support at $8-9 levels. Fundamentally, while revenue grew to $9.56B in 2025, the company reported a net loss of $936M with negative profit margins. Recent Q2 2026 results beat expectations with 30.8% revenue growth and improved gross margins driven by AI cloud services expansion.
Analyst consensus remains positive with 70% buy ratings and 60.3% upside potential, but technical indicators suggest caution. Key risks include ongoing profitability challenges and competitive pressures in China's cloud market. The AI partnership with Xiaomi provides growth catalyst potential, though execution risks persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →